Comparative Pharmacology
Head-to-head clinical analysis: POMALIDOMIDE versus POMALYST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POMALIDOMIDE versus POMALYST.
POMALIDOMIDE vs POMALYST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Immunomodulatory drug with antineoplastic activity; targets cereblon, leading to ubiquitination and degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), resulting in direct cytotoxicity and immune modulation.
Pomalidomide is an immunomodulatory agent with antineoplastic activity. It inhibits proliferation and induces apoptosis of hematopoietic tumor cells. Additionally, it enhances T-cell- and natural killer (NK) cell-mediated immunity and inhibits angiogenesis by blocking the production of pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). The exact mechanism of its immunomodulatory and antineoplastic effects is not fully understood.
4 mg orally once daily on days 1-21 of a 28-day cycle, in combination with dexamethasone.
4 mg orally once daily on days 1-21 of repeated 28-day cycles in combination with dexamethasone, for multiple myeloma; for Kaposi sarcoma, 5 mg orally once daily on days 1-21 of 28-day cycles.
None Documented
None Documented
Clinical Note
moderatePomalidomide + Digoxin
"Pomalidomide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderatePomalidomide + Digitoxin
"Pomalidomide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderatePomalidomide + Deslanoside
"Pomalidomide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderatePomalidomide + Acetyldigitoxin
"Pomalidomide may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life approximately 7.5 hours in patients with normal renal function; prolonged to 9-12 hours in moderate renal impairment.
Terminal elimination half-life is approximately 7.5 hours in patients with multiple myeloma, allowing for once-daily dosing without accumulation at steady state.
Renal (73% as unchanged drug and metabolites), fecal (15%), biliary (minimal).
Approximately 73% of radiolabeled pomalidomide is excreted in urine (primarily as metabolites, with <2% as unchanged drug) and 15% in feces. Renal clearance is the major elimination pathway.
Category C
Category C
Immunomodulatory Agent
Immunomodulatory Agent